Literature DB >> 26004988

Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer.

Jeremy Yuen Chun Teoh1, Peter Ka Fung Chiu1, Samson Yun Sang Chan1, Darren Ming Chun Poon2, Ho-Yuen Cheung3, Simon See Ming Hou1, Chi-Fai Ng1,4.   

Abstract

We investigated the fracture risk after androgen deprivation therapy (ADT) for prostate cancer in the Chinese population. All Chinese prostate cancer patients who were treated primarily by radical prostatectomy or radiotherapy, with or without further ADT, from year 2000 to 2009 were reviewed. We compared the fracture risk in patients who were given ADT (ADT group) with those who were not given any ADT (non-ADT group). Potential risk factors including age, diabetes mellitus, hypertension, hyperlipidemia, ischemic heart disease and performance status were reviewed. The fracture risk was analyzed with Kaplan-Meier and multivariate Cox regression analyses. Our cohort consisted of 200 patients in the non-ADT group and 252 patients in the ADT group. The ADT group was shown to have higher fracture risk (p = 0.036) upon Kaplan-Meier analysis. Upon multivariate Cox regression analyses, diabetes mellitus (HR 4.39, 95% CI 1.08-17.83, p = 0.039), poor performance status (HR 3.14, 95% CI 1.24-8.00, p = 0.016) and the use of ADT (HR 4.89, 95% CI 1.03-23.17, p = 0.045) were associated with increased fracture risk. In conclusion, the fracture risk should be considered while deciding on ADT in Chinese men, especially in diabetic patients with poor performance status.

Entities:  

Keywords:  Androgen deprivation therapy; Chinese; fracture; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26004988     DOI: 10.3109/13685538.2015.1046043

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  4 in total

1.  Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy.

Authors:  Mohammadali Mohammadzadeh Rezaei; Mohammadhadi Mohammadzadeh Rezaei; Alireza Ghoreifi; Behzad Feyzzadeh Kerigh
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

2.  A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.

Authors:  Joseph K M Li; Lynn L Wang; Christine Y P Wong; Peter K F Chiu; Jeremy Y C Teoh; Hilda S W Kwok; Steven C H Leung; Sunny H Wong; Stephen K W Tsui; Chi-Fai Ng
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-13       Impact factor: 5.455

3.  Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.

Authors:  Chi-Ho Lee; Gang Huang; Pak-Hei Chan; Jojo Hai; Chun-Yip Yeung; Carol Ho-Yi Fong; Yu-Cho Woo; Kwan Lun Ho; Ming-Kwong Yiu; Frankie Leung; Tak-Wing Lau; Hung-Fat Tse; Karen Siu-Ling Lam; Chung-Wah Siu
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

Review 4.  Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Authors:  Wai-Kit Ma; Darren Ming-Chun Poon; Chi-Kwok Chan; Tim-Wai Chan; Foon-Yiu Cheung; Lap-Yin Ho; Eric Ka-Chai Lee; Angus Kwong-Chuen Leung; Simon Yiu-Lam Leung; Hing-Shing So; Po-Chor Tam; Philip Wai-Kay Kwong
Journal:  BJU Int       Date:  2019-02-05       Impact factor: 5.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.